呼吸道合胞病毒疫苗的进展。
Progress toward a Respiratory Syncytial Virus Vaccine.
作者信息
Neuzil Kathleen M
机构信息
Department of Medicine and Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
出版信息
Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8. doi: 10.1128/CVI.00037-16.
Abstract
In accompanying papers (P. L. Acosta, M. T. Caballero, and F. P. Polack, Clin Vaccine Immunol 23:189-195, 2016, http://dx.doi.org/10.1128/CVI.00609-15; M. Vissers, I. M. L. Ahout, M. I. de Jonge, and G. Ferwerda, Clin Vaccine Immunol 23:243-245, 2016, http://dx.doi.org/10.1128/CVI.00590-15) in this issue of Clinical and Vaccine Immunology, the history of and immune mechanisms underlying vaccine-enhanced respiratory syncytial virus (RSV) disease and of investigations of mucosal antibodies and their association with viral load in RSV-infected children, respectively, are described. This commentary discusses RSV vaccine candidates, target populations, and the challenges associated with achieving a safe and effective vaccine.
摘要
在本期《临床与疫苗免疫学》的相关论文中（P. L. 阿科斯塔、M. T. 卡瓦列罗和F. P. 波拉克，《临床疫苗免疫学》23:189 - 195，2016年，http://dx.doi.org/10.1128/CVI.00609 - 15；M. 维瑟斯、I. M. L. 阿胡特、M. I. 德容格和G. 费尔韦尔达，《临床疫苗免疫学》23:243 - 245，2016年，http://dx.doi.org/10.1128/CVI.00590 - 15），分别描述了疫苗增强型呼吸道合胞病毒（RSV）疾病的历史及免疫机制，以及对RSV感染儿童黏膜抗体及其与病毒载量关联的研究。本述评讨论了RSV候选疫苗、目标人群以及实现安全有效疫苗所面临的挑战。
相似文献
1
Progress toward a Respiratory Syncytial Virus Vaccine.
Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8. doi: 10.1128/CVI.00037-16.
2
Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.
3
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.
4
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015.
5
Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Virology. 2016 Jul;494:215-24. doi: 10.1016/j.virol.2016.04.014. Epub 2016 Apr 26.
6
Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
PLoS One. 2017 Nov 28;12(11):e0188708. doi: 10.1371/journal.pone.0188708. eCollection 2017.
7
Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice.
Vaccine. 2018 Mar 14;36(12):1561-1569. doi: 10.1016/j.vaccine.2018.02.014. Epub 2018 Feb 10.
8
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development.
Immunity. 2019 Sep 17;51(3):429-442. doi: 10.1016/j.immuni.2019.08.007.
9
A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
Vaccine. 2015 Nov 9;33(45):6085-92. doi: 10.1016/j.vaccine.2015.04.101. Epub 2015 Jun 23.
10
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13.
引用本文的文献
1
Genomic characterization of circulating human respiratory syncytial viruses A and B in Kuwait using whole-genome sequencing.
Microbiol Spectr. 2024 Jul 2;12(7):e0015924. doi: 10.1128/spectrum.00159-24. Epub 2024 May 29.
2
Circulation patterns and molecular epidemiology of human respiratory syncytial virus over five consecutive seasons in Morocco.
Influenza Other Respir Viruses. 2023 Oct 17;17(10):e13203. doi: 10.1111/irv.13203. eCollection 2023 Oct.
3
Dissolving Microneedles Loaded with Nanoparticle Formulation of Respiratory Syncytial Virus Fusion Protein Virus-like Particles (F-VLPs) Elicits Cellular and Humoral Immune Responses.
Vaccines (Basel). 2023 Apr 18;11(4):866. doi: 10.3390/vaccines11040866.
4
Analysis of Template Variations on RNA Synthesis by Respiratory Syncytial Virus Polymerase.
Viruses. 2022 Dec 23;15(1):47. doi: 10.3390/v15010047.
5
Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee.
Ther Adv Infect Dis. 2022 Jul 18;9:20499361221112171. doi: 10.1177/20499361221112171. eCollection 2022 Jan-Dec.
6
Neonatal Immune Responses to Respiratory Viruses.
Front Immunol. 2022 Apr 14;13:863149. doi: 10.3389/fimmu.2022.863149. eCollection 2022.
7
Evolution of respiratory syncytial virus genotype BA in Kilifi, Kenya, 15 years on.
Sci Rep. 2020 Dec 3;10(1):21176. doi: 10.1038/s41598-020-78234-0.
8
Primer-Based RNA Elongation and Promoter Fine Mapping of the Respiratory Syncytial Virus.
J Virol. 2020 Dec 9;95(1). doi: 10.1128/JVI.01897-20.
9
Genomic epidemiology and evolutionary dynamics of respiratory syncytial virus group B in Kilifi, Kenya, 2015-17.
Virus Evol. 2020 Jul 15;6(2):veaa050. doi: 10.1093/ve/veaa050. eCollection 2020 Jul.
10
Structures of the Polymerases.
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.00175-20.
本文引用的文献
1
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.
Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95. doi: 10.1128/CVI.00609-15.
2
Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels.
Clin Vaccine Immunol. 2015 Dec 9;23(3):243-5. doi: 10.1128/CVI.00590-15.
3
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.
Sci Transl Med. 2015 Nov 4;7(312):312ra175. doi: 10.1126/scitranslmed.aac8463.
4
Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
BMC Med. 2015 Mar 10;13:49. doi: 10.1186/s12916-015-0283-x.
5
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665.
6
Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.
J Infect Dis. 2014 Nov 15;210(10):1582-9. doi: 10.1093/infdis/jiu316. Epub 2014 Jun 5.
7
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.
Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.
8
The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.
PLoS One. 2009 Dec 2;4(12):e8088. doi: 10.1371/journal.pone.0008088.
9
The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.
Pediatr Infect Dis J. 2008 Mar;27(3):207-12. doi: 10.1097/INF.0b013e31815ac585.
10
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.
Vaccine. 2003 Jul 28;21(24):3479-82. doi: 10.1016/s0264-410x(03)00355-4.
Zotero 插件